White Paper

Quality 5.0
How AI Is Transforming the Role of the QA Professional

Author: **Kinnari Gandhi, M. Pharm**
RQAP-GCP Director, Quality Assurance — REV Clinical

Co-author: **Hiren Sakhiya, M.Sc** (**Clinical Research Management**)
RQAP-GCP Lead QA Auditor — REV Clinical

REV Clinical™

Executive Summary

The clinical research industry is at an inflection point. AI is no longer theoretical — it is actively deployed across clinical trial operations, quality systems, and regulatory submissions worldwide. The FDA has reviewed over 500 AI-related submissions in seven years, and the landmark Good AI Practice (GAIP) principles jointly issued by the FDA and EMA in January 2026 confirm that the global regulatory framework for AI in clinical research has fundamentally matured.

For QA professionals, this transformation is central. The traditional QA role — defined by inspection, deviation tracking, and compliance — is being redefined. Quality 5.0 frames this new era: AI augments human judgment rather than replacing it, and QA professionals must evolve from compliance enforcers into strategic intelligence partners who govern, validate, and oversee AI-driven quality systems.

This white paper explores Quality 5.0 — how it emerged, what it demands, and how QA professionals can lead this transformation. It examines the AI use case spectrum, FDA and EMA regulatory frameworks, operational challenges of AI adoption, and a practical governance model for integration.

Key Insight:
"AI will not replace QA professionals — but QA professionals who understand AI will lead the future of clinical quality."

Falling behind in both operational performance and regulatory compliance

Clinical trial QA has long operated within a reactive paradigm — audits conducted after events occur, deviations captured retrospectively. While RBQM and QMS advanced the field, the model has remained fundamentally human-dependent — now straining under the volume, velocity, and variety of data generated by today's global trials spanning hundreds of sites, millions of data points, and multi-vendor ecosystems. Compounding this, the FDA and EMA are actively establishing expectations for AI governance, validation, transparency, and lifecycle management — and organizations without these capabilities are falling behind in both operational performance and regulatory compliance.

01 **QA systems cannot match modern trial complexity, creating quality gaps that threaten data integrity and patient safety.**

02 **The QA profession lacks a coherent framework for integrating AI responsibly while preserving human accountability.**

Quality 5.0 is the framework that addresses both challenges simultaneously.

The Scale of AI Adoption in Clinical Research

The integration of AI into clinical development is no longer speculative — the data speaks clearly:

FDA Submissions: Over 500 AI-related submissions reviewed in seven years, spanning pharmacokinetic modeling, manufacturing controls, clinical data analytics, and device software functions.

Market Growth: The global AI in clinical trials market is projected to reach USD 4.8 billion by 2027 (from USD 1.5 billion in 2022; CAGR 25.6%), driven by the need to reduce costs, compress timelines, and improve trial efficiency. (MarketsandMarkets, 2022)

Industry Adoption: A 2024 Tufts CSDD/DIA assessment of 302 respondents across 79 sponsor and CRO organizations found 35.2% had partially or fully implemented AI/ML in trial execution, with 38% specifically using it for TMF management — among the most widely adopted AI applications in clinical operations. (Tufts CSDD/DIA, 2024)

Recruitment Precision: Automated EHR text-mining for cardiovascular trials demonstrated a 79.9% reduction in patients needing to be screened, illustrating AI's potential to significantly improve recruitment precision. (Liu et al., JAMIA, 2024)

Regulatory Milestones Confirming AI Maturity

The pace of regulatory guidance development underscores the institutional commitment to governing AI in clinical research:

Date	Regulatory Development
October 2021	FDA/Health Canada/MHRA release Good Machine Learning Practice (GMLP) guiding principles
September 2024	EMA publishes Reflection Paper on AI in the Medicinal Product Lifecycle
September 2024	FDA establishes CDER AI Council to consolidate AI policy expertise across drug and device centers
January 2025	FDA releases dual guidance: AI to Support Regulatory Decision-Making and AI-Enabled Device Software Functions
January 2026	FDA and EMA jointly release Good AI Practice (GAIP): 10 guiding principles for global AI governance

- **This trajectory signals a permanent shift**: AI governance is now a core regulatory competency, and QA professionals without fluency in this domain will face growing gaps between their oversight capabilities and the systems they oversee.

Scientific and Operational Challenges

The Evolution from Quality 1.0 to Quality 5.0

Understanding the challenges of Quality 5.0 requires appreciating the evolutionary arc of quality management in clinical research. Each generation introduced new capabilities — and new responsibilities. The following framework is now being adapted which maps the Quality evolution framework against the Industry 1.0 to 5.0 progression and applied to clinical research QA practice.

Era	Model	QA Role
Quality 1.0	Inspection-Based	Retrospective audits; errors detected after occurrence; QA as inspector
Quality 2.0	Process Control	SOPs, checklists, standardized workflows; QA as process verifier
Quality 3.0	Quality Management Systems	Formal QMS; CAPA systems; deviation management; QA as system guardian
Quality 4.0	Digital and Risk-Based	EDC, eTMF, RBQM; centralized monitoring; QA as risk evaluator
Quality 5.0	AI-Enabled Human-Centric	AI-assisted review, predictive analytics, signal detection; QA as strategic intelligence partner

Each transition expanded the scope of QA without eliminating the responsibilities of prior eras. Quality 5.0 is not a replacement for Quality 4.0 — it is an elevation of it, layering AI-enabled intelligence onto established quality systems.

Challenge 1: AI Is Not Monolithic

One of the most significant operational challenges is that 'AI' is used as a catch-all term for technologies that carry vastly different levels of clinical and regulatory risk. QA professionals must distinguish between four categories:

AI Type	Application & Risk
Administrative AI	Automates routine tasks (e.g., TMF document classification, duplicate detection). Low risk; does not influence compliance decisions.
Pattern Recognition AI	Anomaly detection (e.g., data entry patterns, AE clustering). Moderate risk; directs QA attention.
Predictive AI	Risk forecasting (e.g., site compliance prediction). Moderate-high risk; influences resource allocation.
Decision-Support AI	Oversight recommendations (e.g., audit scoring, risk dashboards). High risk; shapes compliance decisions.

- **Governance Principle**: Governance and validation must be proportional to the AI's level of influence on clinical quality decisions.

Challenge 2: The 'Black Box' Problem

Many AI models — particularly deep learning architectures — produce outputs without transparent reasoning. Key requirements:

01 **Regulators, especially the EMA, prefer interpretable models.**

02 **Where complex models are used, deploy Explainable AI (XAI) tools such as SHAP (SHapley Additive exPlanations) or LIME (Local Interpretable Model-agnostic Explanations) to reveal the basis for outputs.**

Challenge 3: Data Integrity and Model Drift

AI models trained on historical data can degrade as trial conditions evolve — known as data drift. QA must:

- **Monitor model performance continuously and trigger retraining before quality signals become unreliable.**
- **Enforce a strict training-testing firewall per GMLP principles to prevent data leakage, which can inflate performance estimates and lead to unsafe model deployment.**

Challenge 4: Cybersecurity and AI-Specific Threats

AI systems introduce risks that traditional IT frameworks were not designed to address:

01 **Data Poisoning**: Corrupted data injected into training sets to skew model outputs.

02 **Model Evasion**: Crafted inputs that deceive the AI into incorrect classifications or risk scores.

03 **Model Inversion**: Attempts to reverse-engineer sensitive patient data from model outputs.

QA must now govern the entire machine learning pipeline — not just data outputs, but model integrity itself.

Challenge 5: Regulatory Alignment Across Multiple Frameworks

The regulatory landscape for AI in clinical research is multi-layered and continues to evolve. QA professionals operating in global trials must navigate simultaneously applicable guidance from the FDA, EMA, and jointly issued frameworks, each with distinct but complementary expectations. The challenge lies not in any single framework being complex, but in maintaining consistent governance across a dynamic and expanding regulatory environment.

Proposed Methodology and Solution

The Quality 5.0 Governance Framework

REV Clinical proposes a structured, four-component AI Governance Framework for clinical QA, designed to operationalize the principles of Quality 5.0 across the full lifecycle of AI deployment in clinical research. This framework is fully consistent with current FDA and EMA guidance and is designed to be scalable across trial phases, therapeutic areas, and organizational sizes.

Component 1: Define Intended Use and Assign Risk Tier

Before deployment, every AI tool must have its intended use formally documented, including:

- The clinical or quality question it addresses
- Its context of use (COU) — scope, population, and decision-making role
- Which decisions it informs vs. those that remain exclusively with human QA

Governance requirements then scale with risk tier:

AI Category	Governance Requirements
Administrative AI	Lightweight validation; standard change control; periodic review
Pattern Recognition AI	Formal validation; QA review procedures; escalation pathways
Predictive AI	Full validation; bias assessment; monitoring plan; human override protocols
Decision-Support AI	Comprehensive credibility assessment; regulatory documentation; multidisciplinary oversight board

Component 2: Model Validation and Credibility Assessment

All AI models influencing quality decisions require formal validation per the FDA's 7-Step Credibility Assessment Framework:

01 **Define the clinical/quality question**

02 **Define context of use and model boundaries**

03 **Assess risk of incorrect outputs**

04 **Document architecture, training data, and performance metrics**

05 **Execute validation including demographic bias testing**

06 **Produce a formal Credibility Assessment Report**

07 **Confirm fitness for intended use**

- **Model Cards** — standardized summaries of architecture, limitations, and performance — must be maintained for all validated tools, serving as plain-language "nutrition labels" for regulators, clinicians, and study teams.

Component 3: Human Oversight and Lifecycle Management

Quality 5.0 is explicitly human-centric. The FDA and EMA now assess Human-AI Team Performance — not AI in isolation. QA governance must define:

Who reviews and approves AI outputs before action is taken	What override mechanisms exist when human judgment conflicts with AI
How outputs are communicated to support — not replace — professional judgment	How AI-supported decisions are documented for audit trail defensibility

AI models are dynamic systems requiring active lifecycle management:

- Continuous monitoring for data drift and accuracy degradation
- Formal change control for all updates and retraining events
- Predetermined Change Control Plans (PCCP) to enable model agility without compromising oversight
- Decommissioning protocols for retired tools

- **Critical Principle**: An AI system consistently misinterpreted due to poor interface design or inadequate training is a systemic quality failure. The human-AI team must be assessed together.

Component 4: Documentation and Regulatory Readiness

AI governance documentation must be as inspection-ready as any quality system artifact:

Formal SOPs for AI tool selection, validation, deployment, and monitoring

Transparency protocols communicating model limitations to all stakeholders

Inspection-ready documentation addressing key regulatory questions on AI

GxP-compliant audit trails for all AI-supported quality decisions

Conclusion

Quality 5.0 is not a future state - it is the present reality of clinical research quality assurance. AI is already embedded in TMF management systems, centralized monitoring platforms, safety signal detection tools, and site risk scoring dashboard. Regulatory agencies are not waiting for the industry to catch up; they have already published detailed frameworks, established dedicated governance bodies, and issued binding guidance that defines what good AI practice looks like in clinical development.

The QA profession stands at a pivotal moment. The question is no longer whether AI will transform clinical quality management - it already has. The question is whether QA professionals will lead that transformation or be overtaken by it.

Quality 5.0 offers an empowering answer: the future is not AI versus QA. It is AI plus QA. The QA professional of tomorrow must combine deep regulatory knowledge with technological fluency, risk-based thinking with governance discipline, and human judgment with an understanding of the capabilities and limitations of AI systems. Organizations that invest in building this dual competency - in their people, their processes, and their systems — will be positioned to deliver higher-quality clinical research, faster, with greater consistency and regulatory confidence.

REV Clinical™

- **The Quality 5.0 Commitment**
  "Artificial intelligence will transform how we perform quality oversight, but the responsibility for protecting patients and ensuring the integrity of clinical trials will always remain with us."

Case Study

AI-Assisted TMF Quality Management in a Global Phase III Trial

Note: The following case study is an illustrative scenario developed by REV Clinical based on common operational patterns observed across AI-enabled TMF management implementations in global clinical trials. Specific metrics are representative of outcomes documented in peer-reviewed literature and industry practice rather than a single named study, in order to protect confidentiality. Governance principles described reflect current FDA and EMA regulatory expectations.

Background

A global Phase III clinical trial spanning 42 sites across North America, Europe, and Asia Pacific generated over 85,000 TMF documents across a 36-month study period. The sponsor's QA team had historically performed manual TMF completeness reviews at scheduled intervals, relying on spreadsheet-based tracking and periodic vendor audits. As the document volume grew, the QA team identified an increasing risk of missing or misfiled documents going undetected between scheduled reviews.

The Challenge

Manual review was insufficient to maintain TMF inspection-readiness at the required standard. The QA team estimated that a complete manual review of the TMF at any given point required approximately 3–4 weeks of dedicated QA resource time — a cadence that made real-time quality visibility impossible. Scheduled TMF audits at study milestones continued to identify classification errors, document version discrepancies, and missing required records that had been present in the system for weeks or months before detection.

The AI-Enabled Solution

The organization deployed an Administrative and Pattern Recognition AI-enabled TMF management system. The system was configured to:

Automatically classify incoming documents against the TMF Reference Model and flag documents placed in incorrect sections	Identify version discrepancies — for example, superseded investigator CVs or expired training certificates remaining in the active TMF
Continuously scan for missing expected documents based on study milestones and site activation status	Detect documents uploaded by the wrong site or vendor

The AI system was validated prior to deployment in accordance with the organization's computer systems validation (CSV) procedures, adapted to address the AI-specific requirements of the FDA's credibility assessment framework. A Model Card was produced documenting the system's classification logic, known limitations, and performance metrics.

QA Role and Human Oversight

The AI system did not make compliance determinations — it generated flags and priority queues for QA review. The QA team established a tiered review workflow:

- Critical flags (missing essential documents, expired regulatory submissions) were escalated to QA within 24 hours for review and resolution
- Standard flags (classification discrepancies, version issues) were reviewed weekly through a structured QA dashboard
- All AI-generated flags were documented with QA disposition (confirmed finding, false positive, or escalated) in the organization's quality management system

Outcomes

Metric	Outcome
TMF Review Cycle Time	Reduced from 3-4 weeks to continuous real-time monitoring
Pre-Inspection TMF Completeness	Improved from 87% to 97% at the time of the regulatory inspection
QA Resource Allocation	QA staff time shifted from manual document searching to critical compliance analysis
Inspection Outcome	No TMF-related observations issued during regulatory inspection

Lessons Learned

This case study illustrates several critical Quality 5.0 principles in practice:

01 **AI governance must be proportional to risk. The administrative and pattern-recognition nature of the TMF tool warranted a well-defined but streamlined governance approach compared to predictive or decision-support AI.**

02 **Human oversight is not optional — it is the architecture. The system's design kept QA as the final decision-maker at every step, ensuring regulatory defensibility.**

03 **Model Cards and validation documentation proved essential during the inspection, demonstrating the organization's governance maturity to regulators.**

04 **AI validation is not a one-time event — it is a governance commitment. Performance thresholds must be justified relative to the tool's intended use and clinical risk level, consistent with FDA GMLP principles, and actively monitored throughout the study lifecycle.**

References

All data, statistics, regulatory frameworks, and technical concepts cited in this white paper are sourced from the references listed below. No unsourced claims or self-reasoned statistics are presented as fact.

1. U.S. Food and Drug Administration. (January 2025). Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products. Draft Guidance for Industry. FDA-2024-D-4689. Available at: fda.gov

2. U.S. Food and Drug Administration. (January 2025). Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations. Draft Guidance for Industry and FDA Staff. Available at: fda.gov

3. FDA, Health Canada, and MHRA. (October 2021). Good Machine Learning Practice for Medical Device Development: Guiding Principles. Available at: fda.gov

4. European Medicines Agency. (September 2024). Reflection Paper on the Use of Artificial Intelligence in the Medicinal Product Lifecycle. EMA/CHMP/CVMP/QWP/81697/2024. Available at: ema.europa.eu

5. U.S. Food and Drug Administration and European Medicines Agency. (January 2026). Good AI Practice (GAIP): 10 Guiding Principles for Artificial Intelligence in Drug Development. Joint FDA/EMA Publication.

6. U.S. Food and Drug Administration. (August 2023). Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring. Guidance for Industry. Available at: fda.gov

7. TransCelerate BioPharma. (2020). Risk-Based Quality Management: Recommended Practices. Available at: transceleratebiopharmainc.com

8. European Commission. (2021). Industry 5.0: Towards a Sustainable, Human-Centric and Resilient European Industry. Publications Office of the European Union. doi:10.2777/308407

9. Lundberg, S.M., & Lee, S.I. (2017). A Unified Approach to Interpreting Model Predictions. Advances in Neural Information Processing Systems (NeurIPS), 30.

10. Ribeiro, M.T., Singh, S., & Guestrin, C. (2016). "Why Should I Trust You?": Explaining the Predictions of Any Classifier. Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining.

11. Selvaraju, R.R., Cogswell, M., Das, A., Vedantam, R., Parikh, D., & Batra, D. (2017). Grad-CAM: Visual Explanations from Deep Networks via Gradient-Based Localization. Proceedings of the IEEE International Conference on Computer Vision (ICCV).

12. MarketsandMarkets. (October 2022). Artificial Intelligence (AI) in Clinical Trials Market — Global Forecast to 2027. Press release via PR Newswire. Available at: prnewswire.com

13. Tufts Center for the Study of Drug Development (Tufts CSDD) / Drug Information Association (DIA). (2024). Global Assessment of AI/ML Adoption in Clinical Trial Operations. Survey conducted May–August 2024; published in Applied Clinical Trials Online, February 2026.

14. U.S. Food and Drug Administration. (January 2025). FDA Proposes Framework to Advance Credibility of AI Models Used for Drug and Biological Product Submissions. FDA Press Announcement. Available at: fda.gov/news-events/press-announcements

15. Liu, X., et al. (2024). Artificial intelligence for optimizing recruitment and retention in clinical trials: a scoping review. Journal of the American Medical Informatics Association (JAMIA), 31(11), 2749. doi:10.1093/jamia/ocae208

16. Park, Y., & Kwon, K. (2024). Trends in FDA Data Integrity Enforcement Before and After the COVID-19 Pandemic: An Analysis of 1766 Warning Letters (2016–2023). PubMed/NCBI. PMID: 41071512.

17. Certivo. (2024). FDA Warning Letters & Data Integrity: Lessons from Real Enforcement Actions. Available at: certivo.io/blog/fda-warning-letters-data-integrity

REV Clinical™

Author

Kinnari Gandhi, M. Pharm,
RQAP-GCP Director, Quality Assurance — REV Clinical

Kinnari Gandhi is a seasoned Quality Assurance leader with nearly two decades of experience in clinical research, spanning bioanalytical research, GCP compliance, and quality systems management. She holds a Master of Pharmacy is a credentialed Registered Quality Assurance Professional in Good Clinical Practice (RQAP-GCP). Prior to her current role, Kinnari spent eight years at Veeda Clinical Research as a Senior QA Auditor, where she established expertise in QMS implementation, regulatory and vendor audits, CAPA management, deviation analysis, and risk management. At REV Clinical, she serves as Director of Quality Assurance, leading the development and implementation of GCP/ICH-compliant quality systems across Phase I–IV clinical trial services, medical device research, and multi-therapeutic area programs. Her responsibilities encompass audit oversight, gap assessments, regulatory compliance, and training. Kinnari's deep regulatory fluency and forward-looking perspective on AI-enabled quality governance form the intellectual foundation of this white paper.

Co-Author

Hiren Sakhiya, M.Sc. (Clinical Research Management),
RQAP-GCP Lead QA Auditor — REV Clinical

Hiren Sakhiya is an experienced Quality Assurance professional specializing in GCP compliance, clinical trial auditing, and quality governance within a global CRO environment. He holds a Master of Science in Clinical Research Management and a Bachelor of Pharmacy, and is credentialed as a Registered Quality Assurance Professional in Good Clinical Practice (RQAP-GCP). Hiren began his clinical research career as a Clinical Research Coordinator at Hatkesh Healthcare Foundation, building a strong foundation in site-level trial operations before transitioning into quality assurance. Since joining REV Clinical in 2017, he has progressed through roles of increasing responsibility — from QA Auditor to his current position as Lead Quality Assurance Auditor — contributing to audit programs, compliance monitoring, and quality oversight across multi-site, multi-regional clinical trials. His hands-on experience with the operational realities of clinical QA, combined with his growing expertise in AI-enabled quality management, makes him a key contributor to the practical perspectives and governance frameworks presented in this white paper.

REV Clinical™

REV Clinical™

USA | India | Australia

USA
6501 Truxtun Avenue,
Bakersfield, CA 93309

INDIA
6th Floor, Turquoise IV, SP Ring Road, Nr. Shantipura Circle, Ahmedabad, Gujarat 382210

revclinical.com

At the core of every **clinical trial.**



© 2026 REV Clinical. All Rights Reserved

v. 052026